Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Gross Profit: 2019-2025

Historic Gross Profit for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $2.8 million.

  • Kymera Therapeutics' Gross Profit fell 26.12% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$238,000, marking a year-over-year decrease of 100.27%. This contributed to the annual value of $3.1 million for FY2024, which is 96.06% down from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Gross Profit is $2.8 million, which was down 75.91% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Gross Profit ranged from a high of $47.9 million in Q4 2023 and a low of -$36.6 million during Q4 2024.
  • In the last 3 years, Kymera Therapeutics' Gross Profit had a median value of $10.3 million in 2024 and averaged $10.7 million.
  • Per our database at Business Quant, Kymera Therapeutics' Gross Profit skyrocketed by 463.23% in 2021 and then plummeted by 176.39% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Gross Profit (Quarterly) stood at $15.3 million in 2021, then grew by 5.66% to $16.1 million in 2022, then surged by 196.70% to $47.9 million in 2023, then crashed by 176.39% to -$36.6 million in 2024, then declined by 26.12% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $11.5 million for Q2 2025, and $22.1 million during Q1 2025.